论文部分内容阅读
本品为白色结晶性粉末,在冰醋酸中易溶,在甲醇或水中溶解,在乙二醇、氯仿或丙酮中微溶,在异丙醇中极微溶解,在环己烷或乙醚中几乎不溶。它是一种新的非选择性β肾上腺素能受体阻滞剂,有降低眼内压的作用,主要用于治疗高眼压症和原发性开角型青光眼。据报道,本品具有降压效果肯定、不影响瞳孔大小、副作用少、耐受性好、起效快等优点,且每天只需滴药1～2次,使用方便。1978年在日本召开的第23届眼科学会议上,介绍了它在治疗青光眼方面取得的显著疗效,被认为是局部治疗青光眼的一个重大进展。自1974年以来,本品在英、法、西德、日本、美国先后有商品上市。
This product is white crystalline powder, soluble in glacial acetic acid, dissolved in methanol or water, slightly soluble in ethylene glycol, chloroform or acetone, very slightly soluble in isopropanol, almost in cyclohexane or ether Insoluble. It is a new nonselective β-adrenergic receptor blocker that reduces intraocular pressure and is primarily used for the treatment of ocular hypertension and primary open-angle glaucoma. It is reported that this product has antihypertensive effect is affirmative, does not affect the pupil size, less side effects, good tolerance, rapid onset and other advantages, and only 1 to 2 drops a day, easy to use. The 23rd annual meeting of ophthalmology held in Japan in 1978 introduced its remarkable efficacy in the treatment of glaucoma and is considered to be a major advance in the treatment of glaucoma locally. Since 1974, this product has been listed in Britain, France, West Germany, Japan, the United States.